Abstract

Introduction: Metformin reduces elevated levels of FSH and LH. In some studies, gonadotroph secretory function was inhibited by statins. The aim of the present study was to investigate whether statin therapy modulates the impact of metformin on hypothalamic-pituitary-gonadal axis activity in postmenopausal women. Methods: The study population included 60 postmenopausal women with prediabetes, 40 of whom, because of high cardiovascular risk, received rosuvastatin (20–40 mg daily). One group of rosuvastatin-treated women (group A, n = 23) and all statin-naïve patients (group B, n = 20) were matched for age, glucose homeostasis markers, and gonadotropin levels. Over the entire study period (6 months), these women received metformin. The third group (group C) included 17 rosuvastatin-treated women refusing metformin treatment. We assessed baseline and follow-up plasma lipids, glucose homeostasis markers, and concentrations of FSH, LH, thyrotropin, prolactin, adrenocorticotropic hormone (ACTH), insulin-like growth factor-1, estradiol, progesterone, and anti-Müllerian hormone (in selected patients). Results: Fifty-three women (18 in groups A and B and 17 in group C) completed the study. At study entry, rosuvastatin-treated and statin-naïve women differed in levels of total cholesterol, LDL-cholesterol, and ACTH. In statin-naïve women, metformin reduced FSH levels and tended to reduce LH levels. In rosuvastatin-treated women, metformin decreased FSH and LH levels, and both effects were stronger than in statin-naïve women. Although observed in both groups, the impact on glucose homeostasis markers was more pronounced in individuals not receiving statin therapy. Metformin treatment did not affect circulating levels of lipids, thyrotropin, prolactin, ACTH, insulin-like growth factor-1, estradiol, and anti-Müllerian hormone. In group C, plasma lipids, glucose homeostasis markers, and hormone levels remained at a similar level throughout the study period. Conclusion: The obtained results indicate that statin therapy may enhance gonadotropin-lowering effects of metformin.

© 2023 The Author(s). Published by S. Karger AG, Basel

References Krysiak R, Szkróbka W, Okopień B. The effect of metformin on serum gonadotropin levels in postmenopausal women with diabetes and prediabetes: a pilot study. Exp Clin Endocrinol Diabetes. 2018;126(10):645–50. Krysiak R, Kowalcze K, Okopień B. The impact of metformin on prolactin levels in postmenopausal women. J Clin Pharm Ther. 2021;46(5):1433–40. Billa E, Kapolla N, Nicopoulou SC, Koukkou E, Venaki E, Milingos S, et al. Metformin administration was associated with a modification of LH, prolactin and insulin secretion dynamics in women with polycystic ovarian syndrome. Gynecol Endocrinol. 2009;25(7):427–34. Velija-Ašimi Z. Evaluation of endocrine changes in women with the polycystic ovary syndrome during metformin treatment. Bosn J Basic Med Sci. 2013;13(3):180–5. Krysiak R, Szkróbka W, Bednarska-Czerwińska A, Okopień B. Plasma gonadotropin levels in metformin-treated men with prediabetes: a non-randomized, uncontrolled pilot study. Fundam Clin Pharmacol. 2021;35(2):466–72. Almeida SO, Budoff M. Effect of statins on atherosclerotic plaque.Trends Cardiovasc Med. 2019;29(8):451–5. Krysiak R, Zmuda W, Okopień B. The effect of ezetimibe on androgen production in hypercholesterolemic women with polycystic ovary syndrome. Cardiovasc Ther. 2014;32(5):219–23. Puurunen J, Piltonen T, Puukka K, Ruokonen A, Savolainen MJ, Bloigu R, et al. Statin therapy worsens insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab. 2013;98(12):4798–807. Banaszewska B, Pawelczyk L, Spaczynski RZ, Dziura J, Duleba AJ. Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective randomized cross-over trial. J Clin Endocrinol Metab. 2007;92(2):456–61. Duleba AJ, Banaszewska B, Spaczynski RZ, Pawelczyk L. Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial. Fertil Steril. 2006;85(4):996–1001. Krysiak R, Basiak M, Szkróbka W, Okopień B. The impact of rosuvastatin on hypothalamic-pituitary-testicular axis activity in metformin-treated and metformin-naïve men with low testosterone levels: a pilot study. Pharmacol Rep. 2021;73(5):1465–72. Nieschlag E. Late-onset hypogonadism: a concept comes of age. Andrology. 2020;8(6):1506–11. Kazerooni T, Shojaei-Baghini A, Dehbashi S, Asadi N, Ghaffarpasand F, Kazerooni Y. Effects of metformin plus simvastatin on polycystic ovary syndrome: a prospective, randomized, double-blind, placebo-controlled study. Fertil Steril. 2010;94(6):2208–13. Banaszewska B, Pawelczyk L, Spaczynski RZ, Duleba AJ. Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. J Clin Endocrinol Metab. 2011;96(11):3493–501. Liu Y, Shao Y, Xie J, Chen L, Zhu G. The efficacy and safety of metformin combined with simvastatin in the treatment of polycystic ovary syndrome: a meta-analysis and systematic review. Medicine. 2021;100(31):e26622. Sun J, Yuan Y, Cai R, Sun H, Zhou Y, Wang P, et al. An investigation into the therapeutic effects of statins with metformin on polycystic ovary syndrome: a meta-analysis of randomised controlled trials. BMJ Open. 2015;5(3):e007280. Krysiak R, Kowalcze K, Szkróbka W, Okopień B. The effect of metformin on prolactin levels in patients with drug-induced hyperprolactinemia. Eur J Intern Med. 2016;30:94–8. Łabuzek K, Suchy D, Gabryel B, Bielecka A, Liber S, Okopień B. Quantification of metformin by the HPLC method in brain regions, cerebrospinal fluid and plasma of rats treated with lipopolysaccharide. Pharmacol Rep. 2010;62(5):956–65. Krysiak R, Okopień B. The effect of aggressive rosuvastatin treatment on steroid hormone production in men with coronary artery disease. Basic Clin Pharmacol Toxicol. 2014;114(4):330–5. Kanukula R, Salam A, Rodgers A, Kamel B. Pharmacokinetics of rosuvastatin: a systematic review of randomised controlled trials in healthy adults. Clin Pharmacokinet. 2021;60(2):165–75. Vázquez-Borrego MC, Fuentes-Fayos AC, Herrera-Martínez AD, Venegas-Moreno E, L-López F, Fanciulli A, et al. Statins directly regulate pituitary cell function and exert antitumor effects in pituitary tumors. Neuroendocrinology. 2020;110(11–12):1028–41. Glossmann HH, Lutz OMD. Pharmacology of metformin: an update. Eur J Pharmacol. 2019;865:172782. Keating GM, Robinson DM. Rosuvastatin: a review of its effect on atherosclerosis. Am J Cardiovasc Drugs. 2008;8(2):127–46. Vagenakis AG. Endocrine aspects of menopause. Clin Rheumatol. 1989;8(Suppl 2):48–51. Lennernäs H, Fager G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clin Pharmacokinet. 1997;32(5):403–25. Chin KY. The relationship between follicle-stimulating hormone and bone health: alternative explanation for bone loss beyond oestrogen? Int J Med Sci. 2018;15(12):1373–83. Barron AM, Verdile G, Martins RN. The role of gonadotropins in Alzheimer’s disease: potential neurodegenerative mechanisms. Endocrine. 2006;29(2):257–69. Guber K, Pemmasani G, Malik A, Aronow WS, Yandrapalli S, Frishman WH. Statins and higher diabetes mellitus risk: incidence, proposed mechanisms, and clinical implications. Cardiol Rev. 2021;29(6):314–22. van Stee MF, de Graaf AA, Groen AK. Actions of metformin and statins on lipid and glucose metabolism and possible benefit of combination therapy. Cardiovasc Diabetol. 2018;17(1):94. Tosca L, Solnais P, Ferré P, Foufelle F, Dupont J. Metformin-induced stimulation of adenosine 5' monophosphate-activated protein kinase (PRKA) impairs progesterone secretion in rat granulosa cells. Biol Reprod. 2006;75(3):342–51. van Vliet AK, van Thiel GC, Huisman RH, Moshage H, Yap SH, Cohen LH. Different effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors on sterol synthesis in various human cell types. Biochim Biophys Acta. 1995;1254(1):105–11. Bedenk J, Vrtačnik-Bokal E, Virant-Klun I. The role of anti-Mullerian hormone (AMH) in ovarian disease and infertility. J Assist Reprod Genet. 2020;37(1):89–100. Simpson E, Rubin G, Clyne C, Robertson K, O’Donnell L, Davis S, et al. Local estrogen biosynthesis in males and females. Endocr Relat Cancer. 1999;6(2):131–7. Brown KA, Hunger NI, Docanto M, Simpson ER. Metformin inhibits aromatase expression in human breast adipose stromal cells via stimulation of AMP-activated protein kinase. Breast Cancer Res Treat. 2010;123(2):591–6. Rice S, Pellatt L, Ramanathan K, Whitehead SA, Mason HD. Metformin inhibits aromatase via an extracellular signal-regulated kinase-mediated pathway. Endocrinology. 2009;150(10):4794–801. LaMoia TE, Shulman GI. Cellular and molecular mechanisms of metformin action. Endocr Rev. 2021;42(1):77–96. Miller WL. Disorders in the initial steps of steroid hormone synthesis. J Steroid Biochem Mol Biol. 2017;165(Pt A):18–37. Patil M. Gonadotrophins: the future. J Hum Reprod Sci. 2014;7(4):236–48. Ueno M. Molecular anatomy of the brain endothelial barrier: an overview of the distributional features. Curr Med Chem. 2007;14(11):1199–206. Tosca L, Froment P, Rame C, McNeilly JR, McNeilly AS, Maillard V, et al. Metformin decreases GnRH- and activin-induced gonadotropin secretion in rat pituitary cells: potential involvement of adenosine 5' monophosphate-activated protein kinase (PRKA). Biol Reprod. 2011;84(2):351–62. Dehnavi S, Kiani A, Sadeghi M, Biregani AF, Banach M, Atkin SL, et al. Targeting AMPK by statins: a potential therapeutic approach. Drugs. 2021;81(8):923–33. Malvoisin E, Livrozet JM, El Hajji-Ridah I, Makloufi D, Vincent NJ. Detection of AMP-activated protein kinase in human sera by immuno-isoelectric focusing. J Immunol Methods. 2009;351(1–2):24–9. Mecarelli E, Aigotti R, Asteggiano A, Giacobini P, Chasles M, Tillet Y, et al. Quantitation of endogenous GnRH by validated nano-HPLC-HRMS method: a pilot study on Ewe plasma. Anal Bioanal Chem. 2022;414(26):7623–34. Johnson WD, George VT. Effect of regression to the mean in the presence of within-subject variability. Stat Med. 1991;10(8):1295–302. Author Contacts

Robert Krysiak, rkrysiak@sum.edu.pl

Article / Publication Details

First-Page Preview

Received: September 07, 2022
Accepted: December 28, 2022
Published online: February 15, 2023

Number of Print Pages: 10
Number of Figures: 1
Number of Tables: 2

ISSN: 0031-7012 (Print)
eISSN: 1423-0313 (Online)

For additional information: https://www.karger.com/PHA

Open Access License / Drug Dosage / Disclaimer

This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.